PumaRx Registry Trial
← catalyst calendarNCT06805461 · readout in 1,111 d
Sponsored by RenovoRx (industry) · RNXT — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-01 | actual | When the study began enrolling |
| Primary completion | 2029-09-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors
Intervention
- Device: RenovoCath®
Primary outcomes
what the primary-completion date above is the date OFSafety of RenovoCath® as assessed by the number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.
measured From the time of the first treatment, until 30 days after the last treatment
Performance of RenovoCath® as assessed by the number of participants experiencing adverse events related to the inter-arterial drug delivery procedure.
measured From the time of the first treatment, until 30 days after the last treatment
Permalink · RNXT's whole pipeline · Catalyst calendar · Every registered study · What changed